v3.25.0.1
Related Party Transactions - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Sep. 12, 2024
Mar. 15, 2023
Mar. 13, 2023
Dec. 31, 2024
Dec. 31, 2023
Sep. 11, 2023
Dec. 31, 2020
Related Party Transaction [Line Items]              
Common stock, Shares issued       31,115,341 14,817,696 11,021,248  
Reverse stock split       Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.      
Revenues       $ 6,235 $ 2,826    
Unbilled receivable from related party       0 184    
Deferred revenue current       479 0    
Deferred revenue noncurrent       1,908 0    
Aggregate principal amount       0 377    
Principal and interest repaid       0 377    
Fairmount Funds [Member] | Dianthus [Member]              
Related Party Transaction [Line Items]              
Aggregate principal amount     $ 400        
Interest rate     4.50%        
Principal and interest repaid   $ 400          
Zenas BioPharma Inc [Member]              
Related Party Transaction [Line Items]              
Common stock, Shares issued             156,848
Related party receivable       800 300    
Unbilled receivable from related party         200    
Deferred revenue current         100    
Deferred revenue noncurrent         700    
Zenas BioPharma Inc [Member] | IPO [Member]              
Related Party Transaction [Line Items]              
Price per share $ 17            
Reverse stock split 1-for-8.6831            
Fair value of the investment       $ 100      
Zenas BioPharma Inc [Member] | Tellus Bioventures Llc [Member]              
Related Party Transaction [Line Items]              
Percentage of outstanding shares       5.00%      
Zenas BioPharma Inc [Member] | Fairmount Funds [Member]              
Related Party Transaction [Line Items]              
Percentage of outstanding shares       9.00%      
License Revenue [Member] | Zenas BioPharma Inc [Member]              
Related Party Transaction [Line Items]              
Revenues       $ 5,900 $ 2,800